{
    "clinical_study": {
        "@rank": "100925", 
        "acronym": "Oncology", 
        "arm_group": [
            {
                "arm_group_label": "erlotinib", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death."
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.\nTreatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.\nPatients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.\nIf progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare clinical response (complete response and partial response) by RECIST) rates by\n      RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy"
        }, 
        "brief_title": "Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca", 
        "condition": "Non-small Cell Lung Cancer(NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "an open-label, multi-centre, randomized, phase II study evaluating efficacy of erlotinib\n      monotherapy vs. docetaxel plus cisplatin chemotherapy.\n\n      Patients with histological documented stage IIIA lung adenocarcinoma. The tumor specimens\n      were examined for EGFR gene mutation (Exon 18-21).\n\n      Those with exon 19 deletion and L858R, G719X, L861Q mutation were randomized as erlotinib\n      monotherapy or docetaxel plus cisplatin chemotherapy.\n\n      The randomization will be stratified by center\n\n      Study treatment Patients will receive treatment for 9 weeks unless disease progression,\n      unacceptable toxicity or death.\n\n      Erlotinib arm:\n\n      Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease\n      progression, unacceptable toxicity or death.\n\n      Chemotherapy arm:\n\n      Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with\n      docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.\n\n      Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study\n      treatments due to disease progression or unacceptable toxicity.\n\n      Patients with no disease progression after terminating study treatment will undergo surgical\n      resection and be followed until disease progression is noted, or study end. Survival will be\n      recorded and analyzed.\n\n      If progressive disease or unacceptable toxicity occurs during study treatments, patients\n      will be treated at discretion of investigator according to local protocol.\n\n      Please note:\n\n      \u2022 If it is judged by the investigator to be in the best interest of the patient, patients\n      discontinuing study treatment may receive second-line treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Age \u2265 18 years, male or female\n\n               -  Able to comply with the protocol\n\n               -  Histologically documented stage IIIA lung adenocarcinoma\n\n               -  ECOG performance status 0-2\n\n               -  If the patient has the use coumarin (coumarin) (also to be called coumadin or\n                  warfarin), the patient applies drugs previous 7 days at the experiment to stop\n                  the medicine, and changes to other for to use the medicine.\n\n               -  Life expectancy > 12 weeks\n\n               -  Tumor specimen with EGFR gene mutation of exon 19 deletion and L858R, G719X,\n                  L861Q mutation\n\n               -  Adequate hematological function: ANC \u2265 1.5 x 109/L; platelets \u2265 100 x 109/L, Hb\n                  \u2265 9 g/dL\n\n               -  Data of INR and PTT should be available in patients taking anticoagulants\n                  concomitantly, with INR \u2264 1.5 and PTT \u2264 1.5 times the upper limit of normal (x\n                  ULN ) within 7 days prior to starting study treatment\n\n               -  Adequate liver function: serum bilirubin \u2264 1.5 x ULN; transaminases \u2264 2.5 x ULN\n\n               -  Adequate renal function: 24-hour urine creatinine clearance or creatinine\n                  clearance measured and calculated according to the formula of Cockroft and Gault\n                  \u2265 60ml/min\n\n               -  Negative serum pregnancy test within 7 days of starting study treatment in\n                  pre-menopausal women\n\n               -  Written informed consent.\n\n               -  Patients are willing to complete FACT-L, ED-5Q, or pharmacoeconomic\n                  questionnaires\n\n        Exclusion Criteria:\n\n          -  \u2022 Prior chemotherapy or treatment with another systemic anti-cancer agent (for\n             example monoclonal antibody, tyrosine kinase inhibitor)\n\n               -  Mixed adenocarcinoma and other histological type of lung cancer\n\n               -  Unable to take oral medicine\n\n               -  Pregnant or lactating women\n\n               -  Fertile men or women of childbearing potential not using adequate contraception\n                  (oral contraceptives, intrauterine device or barrier method of contraception in\n                  conjunction with spermicidal jelly or surgically sterile)\n\n               -  Malignancies other than NSCLC within 5 years prior to randomization, except for\n                  adequately treated carcinoma in situ of the cervix, basal or squamous cell skin\n                  cancer, localized prostate cancer treated surgically with curative intent, DCIS\n                  treated surgically with curative intent\n\n               -  Treatment with any other investigational agent, or participation in another\n                  clinical trial within 30 days prior to starting study treatment\n\n               -  Known hypersensitivity to any of the study drugs\n\n               -  Concurrent cancer treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036359", 
            "org_study_id": "201203009MIB"
        }, 
        "intervention": [
            {
                "arm_group_label": "erlotinib", 
                "description": "150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.", 
                "intervention_name": "erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "Tarceva"
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "description": "receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Non-small Cell Lung Cancer(NSCLC)", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "jefferycjyu@ntu.edu.tw", 
                "last_name": "Chong Jen YU, M.D., Ph.D."
            }, 
            "facility": {
                "address": {
                    "city": "Taipei,", 
                    "country": "Taiwan"
                }, 
                "name": "Department of Oncology, National Taiwan University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation.", 
        "overall_contact": {
            "email": "jefferycjyu@ntu.edu.tw", 
            "last_name": "Chong Jen YU, M.D., Ph.D"
        }, 
        "overall_contact_backup": {
            "email": "qoojoan@yahoo.com.tw", 
            "last_name": "Chiung Hui Huang", 
            "phone": "886-2-23123456", 
            "phone_ext": "67779"
        }, 
        "overall_official": {
            "affiliation": "Department of Oncology, National Taiwan University Hospital", 
            "last_name": "Chong-Jen Yu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Event", 
            "safety_issue": "No", 
            "time_frame": "Within 28 days of last study dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}